Fundraising Fox

Lantern Pharma

NASDAQ: LTRN

Texas corporation · 2 known investors

lanternpharma.com ↗

Lantern Pharma develops AI and machine learning tools to identify which patients will respond to oncology drugs before clinical trials, reducing development costs and improving approval odds. The platform serves pharmaceutical companies developing cancer therapies.

AI & Machine LearningBiotechin /lanternpharma@lanternpharma

Founders & leadership

DJ
Donald Jeffrey KeyserChairman of the Board
DR
David R. MargraveChief Financial Officer, Secretary
PS
Panna SharmaChief Executive Officer, President
KG
Kishor G. BhatiaChief Scientific Officer
LT
Lee T. SchalopDirector
VC
Vijay ChandruDirector
DS
David S. SilbersteinDirector
MM
Maria MaccecchiniDirector
AA
Arunkumar AsaithambiDirector
DK
David KeyserDirector
JF
John FucciDirector

Investors · 2

Green Park & Golf VenturesDallas · $500K – $2M
Health WildcattersDallas

Reported raises · per SEC filings

Form D private placements
▶Undisclosed amountofferedMay 2026 · 6 investors · Pharmaceuticals
Rule 506(b)
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpacebiospace.com · Aug 2026Lantern Pharma spins out AI platform into Open-Medicine AI By Investing.comca.investing.com · Aug 2026
Officers, directors & promoters on the filing
  • Donald Jeffrey KeyserDirector
  • David R. MargraveExecutive Officer
  • Panna SharmaExecutive Officer, Director
  • Kishor G. BhatiaExecutive Officer
  • Lee T. SchalopDirector
  • Vijay ChandruDirector
  • David S. SilbersteinDirector
  • Maria MaccecchiniDirector
First sale
May 2026
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedMar 2019 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David SilbersteinDirector
  • John FucciDirector
  • Arunkumar AsaithambiDirector
  • Panna SharmaExecutive Officer, Director
  • Donald KeyserDirector
Offering amount
$6.3M
Amount sold
$2.4M
Proceeds to insiders
$360K
First sale
Mar 2019
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$535KraisedJan 2019 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David SilbersteinDirector
  • Panna SharmaExecutive Officer, Director
  • Arunkumar AsaithambiDirector
  • David KeyserDirector
  • John FucciDirector
Offering amount
$535K
Amount sold
$535K
First sale
Dec 2018
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news